Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 259 | 45,601 | 28% |
| 2020 | 246 | 33,623 | 30% |
| 2021 |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 17% of the cases CMS names in Massachusetts; 120 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 588 | 82,565−2.7%/yr | −2.7%/yr | 44.5 | 75% | 85,900 in 2030+0.7%/yr |
| Pennsylvania | 390 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 29 | 1,871−4.2%/yr | −4.2%/yr | 2.01.0× | 38% | 2,190 in 2030+2.6%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
| 2024 |
| 48,337 |
| 39% |
| 2025 est. | ≈ 48,200 | – |
| 2026 est. | ≈ 50,200 | – |
| 250 |
| 47,380 |
| 32% |
| 2022 | 250 | 43,470 | 35% |
| 2023 | 246 | 49,171 | 38% |
| 2024 | 256 | 48,337 | 39% |
| 2025 from claims | – | 48,231 44,263–51,029 | 40% |
| 2026 forecast | – | 50,161 44,134–57,883 | 39% |
| 2027 forecast | – | 51,452 43,986–61,316 | 40% |
| 2028 forecast | – | 52,776 44,037–64,623 | 40% |
| 2029 forecast | – | 54,133 44,214–67,888 | 40% |
| 2030 forecast | – | 55,523 44,482–71,153 | 40% |
In 2025, 17% hospital outpatient, 76% surgery center, 8% office. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 72,726−1.7%/yr |
| −1.7%/yr |
| 52.4 |
| 80% |
| 74,300 in 2030+0.4%/yr |
| New Jersey | 259 | 44,451−1.6%/yr | −1.6%/yr | 41.8 | 95% | 46,300 in 2030+0.7%/yr |
| Connecticut | 117 | 25,053−0.3%/yr | −0.3%/yr | 74.2 | 80% | 30,200 in 2030+3.2%/yr |
| New Hampshire | 45 | 10,8700%/yr | 0%/yr | 47.3 | 79% | 12,900 in 2030+2.8%/yr |
| Rhode Island | 27 | 7,5280%/yr | 0%/yr | 80.9 | 89% | 11,900 in 2030+7.9%/yr |
| Maine | 24 | 5,023−10%/yr | −10%/yr | 31.2 | 86% | 4,850 in 2030−0.6%/yr |
| Vermont | 17 | 4,085−6.1%/yr | −6.1%/yr | 35.4 | 63% | 6,680 in 2030+8.5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcon leads with 46% of company spending on these surgeons in 2025, +25 pts on 2024.
In 2025, 16 companies reported engagement with Massachusetts’s surgeons worth $204K in consulting, speaking, meals and travel tied to these products, about $798 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.